The Preliminary Safety and Efficacy of RRG001 After Vitrectomy in Subjects With Proliferative Diabetic Retinopathy (PDR)

Who May Qualify: - Able and willing to provide willing to sign a consent form - Age \>= 20 years - Diagnosis of diabetes mellitus (type 1 or type 2) - The study eye diagnosed with PDR, in the opinion of the investigator, requires vitrectomy and postoperative anti-VEGF therapy, or that has undergone vitrectomy and still requires postoperative anti-VEGF therapy - Based on the ETDRS chart, the best-corrected visual acuity (BCVA) of the study eye is ≥ hand motion and ≤ 63 letters Who Should NOT Join This Trial: - Active infection or inflammation in either eye - Previous gene therapy in either eye - Uncontrolled blood pressure（defined as systolic ≥160mmHg or diastolic ≥ 110mmHg by anti-hypertensive treatment) - HbA1c \>12% for diabetes patients at screening - Previous condition not eligible for study drug - History of major ocular surgery (except for PDR) or severe trauma - Currently enrolled in another clinical trial or planning to enroll during the study - Pregnant or lactating women - Other conditions that, in the opinion of the investigator, would preclude participation in the study Study Eye-Exclusion Criteria： - Ocular disorders that, in the opinion of the investigator, would confound the interpretation of study results or affect the administration - CNV or macular edema secondary to any causes other than diabetic retinopathy - Ocular condition considered by the investigator to contraindicate subretinal injection - Diagnosed primary or secondary glaucoma - History of intraocular corticosteroid treatment Always talk to your doctor about whether this trial is right for you.